Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari 'Aldo Moro', Via E. Orabona 4, 70125 Bari, Italy.
Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, 1015 Lausanne, Switzerland.
Eur J Med Chem. 2015 Jan 27;90:583-94. doi: 10.1016/j.ejmech.2014.11.044. Epub 2014 Nov 24.
The effects resulting from the introduction of an oxime group in place of the distal aromatic ring of the diphenyl moiety of LT175, previously reported as a PPARα/γ dual agonist, have been investigated. This modification allowed the identification of new bioisosteric ligands with fairly good activity on PPARα and fine-tuned moderate activity on PPARγ. For the most interesting compound (S)-3, docking studies in PPARα and PPARγ provided a molecular explanation for its different behavior as full and partial agonist of the two receptor isotypes, respectively. A further investigation of this compound was carried out performing gene expression studies on HepaRG cells. The results obtained allowed to hypothesize a possible mechanism through which this ligand could be useful in the treatment of metabolic disorders. The higher induction of the expression of some genes, compared to selective agonists, seems to confirm the importance of a dual PPARα/γ activity which probably involves a synergistic effect on both receptor subtypes.
先前有研究报道,将 LT175 中二苯基部分的远端芳环用肟基团取代,可产生作用。对这种取代的效果进行了研究,LT175 是一种 PPARα/γ 双重激动剂。这种修饰允许鉴定具有相当高的 PPARα 活性和微调的适度 PPARγ 活性的新型生物等排配体。对于最有趣的化合物(S)-3,在 PPARα 和 PPARγ 中的对接研究为其作为两种受体亚型的完全激动剂和部分激动剂的不同行为提供了分子解释。进一步对该化合物进行了研究,在 HepaRG 细胞上进行基因表达研究。所获得的结果允许假设一种可能的机制,通过该配体可用于治疗代谢紊乱。与选择性激动剂相比,某些基因的表达诱导更高,这似乎证实了双重 PPARα/γ 活性的重要性,这可能涉及对两种受体亚型的协同作用。